Cellectis (CLLS) Scheduled to Post Earnings on Monday

Cellectis (NASDAQ:CLLSGet Free Report) will issue its quarterly earnings data after the market closes on Monday, November 4th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Cellectis (NASDAQ:CLLSGet Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. The firm had revenue of $9.50 million during the quarter, compared to analyst estimates of $6.00 million. On average, analysts expect Cellectis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cellectis Trading Up 3.0 %

Shares of CLLS opened at $1.87 on Thursday. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.39. Cellectis has a 12-month low of $0.96 and a 12-month high of $3.77. The firm has a 50-day moving average price of $2.13 and a 200 day moving average price of $2.30. The firm has a market capitalization of $104.15 million, a P/E ratio of -1.41 and a beta of 3.09.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Cellectis in a report on Monday. They issued a “sell” rating for the company.

Get Our Latest Analysis on Cellectis

About Cellectis

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Further Reading

Earnings History for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.